Joshua Richter, MD, Talks Results from LINKER-MM1 Study

Home > Myeloma > Joshua Richter, MD, Talks Results from LINKER-MM1 Study Dr. Richter of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, joins Blood Cancers Today from the 20th International Myeloma Society Annual Meeting and Exposition to discuss data from the phase II LINKER-MM1 study. He spoke about his poster presentation, which focused on the evaluation of the efficacy and safety of two linvoseltamab dosing regimens, 50 mg and 200 mg. The study evaluated the two doses in

Read the full article here

Source: www.bloodcancerstoday.com

Categories: Partners & KOLs, General Medicine News

Tags: IMS23,IMS2023

Tweets with this article

Blood Cancers Today

Catching up on all the data coming out of #IMS23? In this video interview, @JoshuaRichterMD of @TischCancer, @IcahnMountSinai, @MountSinaiNYC discusses data from the LINKER1-MM study that he presented at #IMS2023. 📺https://t.co/sk2FBrUIGX https://t.co/1lDRUqWXGs

Omega-3s and brain health: what the science really says | Dr. Bill Harris & Prof. Sarah Berry

Podcast Episode · ZOE Science & Nutrition · 07/24/2025 · 1h 4m

Joel Kahn MD, FACC July 24, 2025

Atherosclerosis and Inflammation: Are the Rules of the Game Changing w | JIR

Summarizing knowledge regarding the role of inflammation in atherosclerosis and evaluate therapeutic potential of biologic agents targeting specific pathways.

Joel Kahn MD, FACC July 24, 2025

7 celebrity vegans who make cruelty-free living look effortlessly cool

You’ve seen them on screen and stage—now discover how they’re transforming culture through conscious living.

Joel Kahn MD, FACC July 24, 2025

The magic number of steps you should actually be getting every day:…

Hint: It’s not 10,000.

Joel Kahn MD, FACC July 24, 2025

Creatine monohydrate supplementation for older adults and clinical populations – PubMed

CrM has multiple benefits in older adults and may have application for treating age-related sarcopenia, osteoporosis, frailty, and those with metabolic and neuromuscular disorders.

Joel Kahn MD, FACC July 24, 2025

New Duke study finds obesity rises with caloric intake, not couch time

People in richer countries aren’t moving less — they’re just eating more. A new Duke study shows that diet, not laziness, is fueling the obesity…

Joel Kahn MD, FACC July 24, 2025

The Effect of Theobromine Supplementation on HDL-c Subclasses (HDL-c2, HDL-c3), HDL-c2/HDL-c3 Ratio, and Gene Expression of PPAR-α and Sirt1 in Subjects With Metabolic Syndrome: A Randomized Controlled Clinical Trial – PubMed

Several studies have reported the beneficial effects of theobromine (TB) on metabolic syndrome (MetS) indices and cardiovascular risk factors. However, the findings are controversial. The…

Joel Kahn MD, FACC July 24, 2025

Avoid the lone star tick; its alpha-gal molecule may flip a victim’s immune system against red meat – NKyTribune

By Heather Norman-Burgdolf University of Kentucky Ticks are bad news in general, but the lone star tick brings an extra problem: it can leave behind…

Joel Kahn MD, FACC July 24, 2025

Targeting KRAS: An Expanding Goal of GI Cancer Research | GI Oncology Now

KRAS mutations drive GI cancers, but new inhibitors, vaccines, and combinations are advancing efforts to target them.

July 23, 2025

Paper: 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in…

Rahul Banerjee, MD July 23, 2025

Related Articles